Protective effects of matrine against progression of high-fructose diet-induced steatohepatitis by enhancing antioxidant and anti-inflammatory defences involving Nrf2 translocation

Food and Chemical Toxicology

Volumn 55, Issue , 2013, Pages 70-77

  Zhang, He Fang ^a   Shi, Li Juan ^a   Song, Guang Yao ^a   Cai, Zhi Gang ^a   Wang, Chao ^b   An, Rui Jin ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b HEBEI GENERAL HOSPITAL   (China)

Author keywords

Anti inflammation; Antioxidant enzyme; Hepatoprotective effect; High fructose diet; Matrine; Nonalcoholic steatohepatitis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; FAT DROPLET; GLUTATHIONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MALONALDEHYDE; MATRINE; TRANSCRIPTION FACTOR NRF2; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CELL INFILTRATION; CELL NUCLEUS; CHOLESTEROL LIVER LEVEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; DRUG RESEARCH; HYPERGLYCEMIA; INFLAMMATORY CELL; INSULIN RESISTANCE; LIVER CELL; LIVER PROTECTION; LOW DRUG DOSE; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RAT; TREATMENT DURATION; UPREGULATION;

ALKALOIDS; ANIMALS; ANTIOXIDANTS; DISEASE PROGRESSION; FATTY LIVER; FRUCTOSE; INFLAMMATION; MALE; NF-E2-RELATED FACTOR 2; PROTEIN TRANSPORT; QUINOLIZINES; RATS; RATS, WISTAR;

EID: 84873248461     PISSN: 02786915     EISSN: 18736351     Source Type: Journal    
DOI: 10.1016/j.fct.2012.12.043     Document Type: Article

References (66)

1. Abdelmalek M.F., Suzuki A., Guy C., Unalp-Arida A., Colvin R., Johnson R.J., Diehl A.M. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology 2010, 51:1961-1971.
2. Ackerman Z., Oron-Herman M., Grozovski M., Rosenthal T., Pappo O., Link G., Sela B.A. Fructose-induced fatty liver disease: hepatic effects of blood pressure and plasma triglyceride reduction. Hypertension 2005, 45:1012-1018.
3. Adams L.A., Lymp J.F., St Sauver J., Sanderson S.O., Lindor K.D., Feldstein A., Angulo P. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005, 129:113-121.
4. Angulo P., Lindor K.D. Insulin resistance and mitochondrial abnormalities in NASH: a cool look into a burning issue. Gastroenterology 2001, 120:1281-1285.
5. Asghar M., George L., Lokhandwala M.F. Exercise decreases oxidative stress and inflammation and restores renal dopamine D1 receptor function in old rats. American Journal of Physiology. Renal Physiology 2007, 293:F914-F919.
6. Busserolles J., Gueux E., Rock E., Demigne C., Mazur A., Rayssiguier Y. Oligofructose protects against the hypertriglyceridemic and pro-oxidative effects of a high fructose diet in rats. Journal of Nutrition 2003, 133:1903-1908.
7. Chalasani N., Deeg M.A., Crabb D.W. Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis. The American Journal of Gastroenterology 2004, 99:1497-1502.
8. Chen H.M., Chen M.F., Shyr M.H. Prostacyclin analogue (OP-2507) attenuates hepatic microcirculatory derangement, energy depletion, and lipid peroxidation in a rat model of reperfusion injury. The Journal of Surgical Research 1998, 80:333-338.
9. Cheng H., Xia B., Zhang L., Zhou F., Zhang Y.X., Ye M., Hu Z.G., Li J., Wang Z.L., Li C., Guo Q.S. Matrine improves 2,4,6-trinitrobenzene sulfonic acid-induced colitis in mice. Pharmacological Research: The Official Journal of the Italian Pharmacological Society 2006, 53:202-208.
10. Davail, S., Rideau, N., Bernadet, M.D., Andre, J.M., Guy, G., Hoo-Paris, R., 2005. Effects of dietary fructose on liver steatosis in overfed mule ducks. Hormone and Metabolic Research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 37, 32-35.
11. Day C.P. Pathogenesis of steatohepatitis. Best Practice and Research. Clinical Gastroenterology 2002, 16:663-678.
12. Farombi E.O., Surh Y.J. Heme oxygenase-1 as a potential therapeutic target for hepatoprotection. Journal of Biochemistry and Molecular Biology 2006, 39:479-491.
13. Farrell G.C., Larter C.Z. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006, 43:S99-S112.
14. Gao H.Y., Li G.Y., Lou M.M., Li X.Y., Wei X.Y., Wang J.H. Hepatoprotective effect of matrine salvianolic acid B salt on carbon tetrachloride-induced hepatic fibrosis. Journal of Inflammation (London) 2012, 9:16.
15. Garcia-Ruiz C., Colell A., Morales A., Kaplowitz N., Fernandez-Checa J.C. Role of oxidative stress generated from the mitochondrial electron transport chain and mitochondrial glutathione status in loss of mitochondrial function and activation of transcription factor nuclear factor-kappa B: studies with isolated mitochondria and rat hepatocytes. Molecular Pharmacology 1995, 48:825-834.
16. Gong P., Cederbaum A.I., Nieto N. Heme oxygenase-1 protects HepG2 cells against cytochrome P450 2E1-dependent toxicity. Free Radical Biology and Medicine 2004, 36:307-318.
17. Gross L.S., Li L., Ford E.S., Liu S. Increased consumption of refined carbohydrates and the epidemic of type 2 diabetes in the United States: an ecologic assessment. American Journal of Clinical Nutrition 2004, 79:774-779.
18. Henao-Mejia J., Elinav E., Jin C., Hao L., Mehal W.Z., Strowig T., Thaiss C.A., Kau A.L., Eisenbarth S.C., Jurczak M.J., Camporez J.P., Shulman G.I., Gordon J.I., Hoffman H.M., Flavell R.A. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012, 482:179-185.
19. Hu Z.L., Zhang J.P., Qian D.H., Lin W., Xie W.F., Zhang X.R., Chen W.Z. Effects of matrine on mouse splenocyte proliferation and release of interleukin-1 and -6 from peritoneal macrophages in vitro. Zhongguo yao li xue bao = Acta Pharmacologica Sinica 1996, 17:259-261.
20. Hu Z.L., Zhang J.P., Wan M.B., Yu X.B., Lin W., Qian D.H. Effect of matrine on mouse hepatitis and tumor necrosis factor production induced by Propionibacterium acnes/lipopolysaccharides. Yao xue xue bao = Acta Pharmaceutica Sinica 1996, 31:662-665.
21. Hu Z.L., Zhang J.P., Yu X.B., Lin W., Qian D.H., Wan M.B. Effect of matrine on lipopolysaccharides/d-galactosamine-induced hepatitis and tumor necrosis factor release from macrophages in vitro. Zhongguo yao li xue bao = Acta Pharmacologica Sinica 1996, 17:351-353.
22. Ishii T., Itoh K., Takahashi S., Sato H., Yanagawa T., Katoh Y., Bannai S., Yamamoto M. Transcription factor Nrf2 coordinately regulates a group of oxidative stress-inducible genes in macrophages. The Journal of Biological Chemistry 2000, 275:16023-16029.
23. Jin W., Wang H., Yan W., Xu L., Wang X., Zhao X., Yang X., Chen G., Ji Y. Disruption of Nrf2 enhances upregulation of nuclear factor-kappaB activity, proinflammatory cytokines, and intercellular adhesion molecule-1 in the brain after traumatic brain injury. Mediators of Inflammation 2008, 2008:725174.
24. Kathirvel E., Chen P., Morgan K., French S.W., Morgan T.R. Oxidative stress and regulation of anti-oxidant enzymes in cytochrome P4502E1 transgenic mouse model of non-alcoholic fatty liver. Journal of Gastroenterology and Hepatology 2010, 25:1136-1143.
25. Kwak M.K., Itoh K., Yamamoto M., Sutter T.R., Kensler T.W. Role of transcription factor Nrf2 in the induction of hepatic phase 2 and antioxidative enzymes in vivo by the cancer chemoprotective agent, 3H-1, 2-dimethiole-3-thione. Molecular Medicine 2001, 7:135-145.
26. Le K.A., Tappy L. Metabolic effects of fructose. Current Opinion in Clinical Nutrition and Metabolic Care 2006, 9:469-475.
27. Lefkowitch J.H., Haythe J.H., Regent N. Kupffer cell aggregation and perivenular distribution in steatohepatitis. Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc 2002, 15:699-704.
28. Li X.K., Matin A.F., Suzuki H., Uno T., Yamaguchi T., Harada Y. Effect of protease inhibitor on ischemia/reperfusion injury of the rat liver. Transplantation 1993, 56:1331-1336.
29. Lickteig A.J., Fisher C.D., Augustine L.M., Cherrington N.J. Genes of the antioxidant response undergo upregulation in a rodent model of nonalcoholic steatohepatitis. Journal of Biochemical and Molecular Toxicology 2007, 21:216-220.
30. Lin W., Zhang J.P., Hu Z.L., Qian D.H. Inhibitory effect of matrine on lipopolysaccharide-induced tumor necrosis factor and interleukin-6 production from rat Kupffer cells. Yao xue xue bao = Acta Pharmaceutica Sinica 1997, 32:93-96.
31. Liu J., Zhu M., Shi R., Yang M. Radix Sophorae flavescentis for chronic hepatitis B: a systematic review of randomized trials. The American Journal of Chinese Medicine 2003, 31:337-354.
32. Long Y., Lin X.T., Zeng K.L., Zhang L. Efficacy of intramuscular matrine in the treatment of chronic hepatitis B. Hepatobiliary and Pancreatic Diseases International: HBPD INT 2004, 3:69-72.
33. Mao L., Henderson G. Antifeedant activity and acute and residual toxicity of alkaloids from Sophora flavescens (leguminosae) against formosan subterranean termites (Isoptera: Rhinotermitidae). Journal of Economic Entomology 2007, 100:866-870.
34. Morse D., Choi A.M. Heme oxygenase-1: from bench to bedside. American Journal of Respiratory and Critical Care Medicine 2005, 172:660-670.
35. Motohashi H., Yamamoto M. Nrf2-Keap1 defines a physiologically important stress response mechanism. Trends in Molecular Medicine 2004, 10:549-557.
36. Nomura K., Yamanouchi T. The role of fructose-enriched diets in mechanisms of nonalcoholic fatty liver disease. Journal of Nutritional Biochemistry 2012, 23:203-208.
37. Ouyang X., Cirillo P., Sautin Y., McCall S., Bruchette J.L., Diehl A.M., Johnson R.J., Abdelmalek M.F. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. Journal of Hepatology 2008, 48:993-999.
38. Pawate S., Shen Q., Fan F., Bhat N.R. Redox regulation of glial inflammatory response to lipopolysaccharide and interferongamma. Journal of Neuroscience Research 2004, 77:540-551.
39. Pei R.J., Xiao L., Fan X.P., Liu X.J. The effects of matrine on mouse immune functions. Strait Pharmaceutical Journal 1998, 10:7-8.
40. Pessayre D., Mansouri A., Fromenty B. Nonalcoholic steatosis and steatohepatitis. V. Mitochondrial dysfunction in steatohepatitis. American Journal of Physiology, Gastrointestinal and Liver Physiology 2002, 282:G193-G199.
41. Rahman I., Kode A., Biswas S.K. Assay for quantitative determination of glutathione and glutathione disulfide levels using enzymatic recycling method. Nature Protocols 2006, 1:3159-3165.
42. Reid A.E. Nonalcoholic steatohepatitis. Gastroenterology 2001, 121:710-723.
43. Rutledge A.C., Adeli K. Fructose and the metabolic syndrome: pathophysiology and molecular mechanisms. Nutrition Reviews 2007, 65:S13-S23.
44. Sanyal A.J., Campbell-Sargent C., Mirshahi F., Rizzo W.B., Contos M.J., Sterling R.K., Luketic V.A., Shiffman M.L., Clore J.N. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001, 120:1183-1192.
45. Sato A., Kawano H., Notsu T., Ohta M., Nakakuki M., Mizuguchi K., Itoh M., Suganami T., Ogawa Y. Antiobesity effect of eicosapentaenoic acid in high-fat/high-sucrose diet-induced obesity: importance of hepatic lipogenesis. Diabetes 2010, 59:2495-2504.
46. Schwartz D.M., Wolins N.E. A simple and rapid method to assay triacylglycerol in cells and tissues. Journal of Lipid Research 2007, 48:2514-2520.
47. Seki S., Kitada T., Yamada T., Sakaguchi H., Nakatani K., Wakasa K. In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. Journal of Hepatology 2002, 37:56-62.
48. Shan X.Q., Aw T.Y., Jones D.P. Glutathione-dependent protection against oxidative injury. Pharmacology and Therapeutics 1990, 47:61-71.
49. Spruss A., Bergheim I. Dietary fructose and intestinal barrier: potential risk factor in the pathogenesis of nonalcoholic fatty liver disease. Journal of Nutritional Biochemistry 2009, 20:657-662.
50. Su G.L. Lipopolysaccharides in liver injury: molecular mechanisms of Kupffer cell activation. American Journal of Physiology, Gastrointestinal and Liver Physiology 2002, 283:G256-G265.
51. Sugimoto H., Okada K., Shoda J., Warabi E., Ishige K., Ueda T., Taguchi K., Yanagawa T., Nakahara A., Hyodo I., Ishii T., Yamamoto M. Deletion of nuclear factor-E2-related factor-2 leads to rapid onset and progression of nutritional steatohepatitis in mice. American Journal of Physiology, Gastrointestinal and Liver Physiology 2010, 298:G283-G294.
52. Susca M., Grassi A., Zauli D., Volta U., Lenzi M., Marchesini G., Bianchi F.B., Ballardini G. Liver inflammatory cells, apoptosis, regeneration and stellate cell activation in non-alcoholic steatohepatitis. Digestive and Liver Disease: Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2001, 33:768-777.
53. Tappy L., Le K.A. Metabolic effects of fructose and the worldwide increase in obesity. Physiological Reviews 2010, 90:23-46.
54. Thimmulappa R.K., Lee H., Rangasamy T., Reddy S.P., Yamamoto M., Kensler T.W., Biswal S. Nrf2 is a critical regulator of the innate immune response and survival during experimental sepsis. The Journal of Clinical Investigation 2006, 116:984-995.
55. Tilg H., Diehl A.M. Cytokines in alcoholic and nonalcoholic steatohepatitis. The New England Journal of Medicine 2000, 343:1467-1476.
56. Tripathi D.N., Jena G.B. Astaxanthin intervention ameliorates cyclophosphamide-induced oxidative stress, DNA damage and early hepatocarcinogenesis in rat: role of Nrf2, p53, p38 and phase-II enzymes. Mutation Research 2010, 696:69-80.
57. Vuppalanchi R., Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management. Hepatology 2009, 49:306-317.
58. Wang X.Y., Liang L., Chang J.L., Yang M.H., Li Z.G. Toxicity of matrine in Kunming mice. Nan fang yi ke da xue xue bao = Journal of Southern Medical University 2010, 30:2154-2155.
59. Wills E.D. Mechanisms of lipid peroxide formation in animal tissues. The Biochemical Journal 1966, 99:667-676.
60. Yesilova Z., Yaman H., Oktenli C., Ozcan A., Uygun A., Cakir E., Sanisoglu S.Y., Erdil A., Ates Y., Aslan M., Musabak U., Erbil M.K., Karaeren N., Dagalp K. Systemic markers of lipid peroxidation and antioxidants in patients with nonalcoholic fatty liver disease. The American Journal of Gastroenterology 2005, 100:850-855.
61. Zhang B., Liu Z.Y., Li Y.Y., Luo Y., Liu M.L., Dong H.Y., Wang Y.X., Liu Y., Zhao P.T., Jin F.G., Li Z.C. Antiinflammatory effects of matrine in LPS-induced acute lung injury in mice. European Journal of Pharmaceutical Sciences: Official Journal of the European Federation for Pharmaceutical Sciences 2011, 44:573-579.
62. Zhang F., Wang X., Tong L., Qiao H., Li X., You L., Jiang H., Sun X. Matrine attenuates endotoxin-induced acute liver injury after hepatic ischemia/reperfusion in rats. Surgery Today 2011, 41:1075-1084.
63. Zhang J.P., Zhang M., Jin C., Zhou B., Xie W.F., Guo C., Zhang C., Qian D.H. Matrine inhibits production and actions of fibrogenic cytokines released by mouse peritoneal macrophages. Acta Pharmacologica Sinica 2001, 22:765-768.
64. Zhang J.P., Zhang M., Zhou J.P., Liu F.T., Zhou B., Xie W.F., Guo C. Antifibrotic effects of matrine on in vitro and in vivo models of liver fibrosis in rats. Acta Pharmacologica Sinica 2001, 22:183-186.
65. Zhu X.-H., Qiu Y.-D., Shen H., Shi M.-K., Ding Y.-T. Effect of matrine on Kupffer cell activation in cold ischemia reperfusion injury of rat liver. World Journal of Gastroenterology 2002, 8:1112-1116.
66. Zhu X., Qiu Y., Shi M., Ding Y. Matrine protects sinusoidal endothelial cells from cold ischemia and reperfusion injury in rat orthotopic liver transplantation. Annals of Clinical and Laboratory Science 2003, 33:216-225.